Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye doctor: new study aims to spot Blindness-Causing diseases

NCT ID NCT07497815

Diagnosis Sponsor: Marisse Masis-Solano Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will develop and test an artificial intelligence system to detect common eye diseases like glaucoma, cataracts, and diabetic retinopathy using 15,000 existing eye images from Costa Rican patients. The goal is to create a tool that works accurately for local populations, since AI systems trained on other ethnic groups may not perform as well. No new treatments or patient contact are involved—it's purely a diagnostic technology validation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a reliable AI tool for diagnosing eye diseases in Latin American populations, improving early detection and reducing blindness.
What could go wrong
This is an early-stage observational study using existing images, not a clinical treatment trial. The AI may not perform as well in real-world settings or on different populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Ophthalmic medical images from adult patients (≥18 years) who received eye care at two ophthalmology centers in Costa Rica (Asociados de Mácula y Vítreo de Costa Rica in San José, and Centro Ocular in Heredia). Images were captured during routine clinical care for various clinical indications, including routine screening, follow-up visits, and diagnostic evaluations. The study population represents the real-world spectrum of patients seeking ophthalmology care in these centers, including healthy individuals, patients with various stages of eye diseases, and patients with multiple ocular pathologies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Image corresponds to patient ≥18 years of age at time of capture * Image modality is one of: fundus photography, posterior segment OCT, anterior segment photography, automated perimetry, or video-OCT * Image quality sufficient for diagnostic interpretation (adequate resolution, focus, illumination, complete visualization of anatomical area of interest, no major artifacts) * Minimum clinical data available (age or age group, sex, and diagnosis or clinical indication) * Image captured during routine clinical care (not specifically for research) * No patient objection to use of medical data for research (when applicable per center policy) Exclusion Criteria: CLINICAL: * Images from eyes with recent intraocular surgery (\<3 months) * Images from eyes with severe ocular trauma distorting anatomy * Images from patients with rare or unique ocular pathologies not allowing generalization * Images post-recent laser treatment where acute changes may confuse analysis TECHNICAL: * Severely degraded image quality (extreme blur, severe under/overexposure, major artifacts preventing interpretation) * Duplicate images of same eye on same date * Images with missing or clearly erroneous metadata * Images in non-standard or corrupted formats that cannot be processed Sex/Gender: All Minimum Age: 18 Years Maximum Age: No limit Accepts Healthy Volunteers: Yes (images of healthy eyes without pathology are included as controls)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract diabetic retinopathy glaucoma keratoconus macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Diabetic retinopathy (DR) Glaucoma Keratoconus Macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asociados de Mácula y Vítreo de Costa Rica

    San José, Provincia de San José, Costa Rica

  • Centro Ocular

    Heredia, Centro, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.